Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

British Journal of Haematology

Volumn 168, Issue 5, 2015, Pages 646-653

  Daver, Naval ^a   Kantarjian, Hagop ^a   Marcucci, Guido ^b   Pierce, Sherry ^a   Brandt, Mark ^a   Dinardo, Courtney ^a   Pemmaraju, Naveen ^a   Garcia Manero, Guillermo ^a   O'Brien, Susan ^a   Ferrajoli, Alessandra ^a   Verstovsek, Srdan ^a   Popat, Uday ^a   Hosing, Chitra ^a   Anderlini, Paolo ^a   Borthakur, Gautam ^a   Kadia, Tapan ^a   Cortes, Jorge ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute promyelocytic leukaemia; All trans retinoic acid; Arsenic; Leukapheresis; Outcomes

Indexed keywords

ARSENIC TRIOXIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; RETINOIC ACID; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HYPERLEUKOCYTOSIS; LEUKAPHERESIS; LEUKOCYTE COUNT; LEUKOCYTE DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; REMISSION; RETROSPECTIVE STUDY; TREATMENT PLANNING; BLOOD; CLINICAL TRIAL; FOLLOW UP; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; MIDDLE AGED; SURVIVAL RATE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKAPHERESIS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MIDDLE AGED; OXIDES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRETINOIN;

EID: 84922949829     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13189     Document Type: Article

References (29)

1. Alimoghaddam, K., Ghavamzadeh, A., Jahani, M., Mousavi, A., Iravani, M., Rostami, S., Ghaffari, H., Hosseini, R. & Jalili, M. (2011) Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Archives of Iranian Medicine, 14, 167-169.
2. Bug, G., Anargyrou, K., Tonn, T., Bialleck, H., Seifried, E., Hoelzer, D. & Ottmann, O.G. (2007) Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion, 47, 1843-1850.
3. Burnett, A.K., Grimwade, D., Solomon, E., Wheatley, K. & Goldstone, A.H. (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood, 93, 4131-4143.
4. Chang, M.C., Chen, T.Y., Tang, J.L., Lan, Y.J., Chao, T.Y., Chiu, C.F. & Ho, H.T. (2007) Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. American Journal of Hematology, 82, 976-980.
5. Chen, G.Q., Shi, X.G., Tang, W., Xiong, S.M., Zhu, J., Cai, X., Han, Z.G., Ni, J.H., Shi, G.Y., Jia, P.M., Liu, M.M., He, K.L., Niu, C., Ma, J., Zhang, P., Zhang, T.D., Paul, P., Naoe, T., Kitamura, K., Miller, W., Waxman, S., Wang, Z.Y., de The, H., Chen, S.J. & Chen, Z. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 89, 3345-3353.
6. De Santis, G.C., de Oliveira, L.C., Romano, L.G., Almeida Prado Bde, P. Jr, Simoes, B.P., Rego, E.M., Covas, D.T. & Falcao, R.P. (2011) Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia. Journal of Clinical apheresis, 26, 181-185.
7. Estey, E.H., Keating, M.J., McCredie, K.B., Bodey, G.P. & Freireich, E.J. (1982) Causes of initial remission induction failure in acute myelogenous leukemia. Blood, 60, 309-315.
8. Estey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D. & Kantarjian, H. (2006) Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood, 107, 3469-3473.
9. Fenaux, P., Castaigne, S., Chomienne, C., Dombret, H. & Degos, L. (1992) All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia, 6, 64-66.
10. Fenaux, P., Le Deley, M.C., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M.T. & Bowen, D. (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood, 82, 3241-3249.
11. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., Fey, M., Rayon, C., Huguet, F., Sotto, J.J., Gardin, C., Makhoul, P.C., Travade, P., Solary, E., Fegueux, N., Bordessoule, D., Miguel, J.S., Link, H., Desablens, B., Stamatoullas, A., Deconinck, E., Maloisel, F., Castaigne, S., Preudhomme, C. & Degos, L. (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood, 94, 1192-1200.
12. Giles, F.J., Shen, Y., Kantarjian, H.M., Korbling, M.J., O'Brien, S., Anderlini, P., Donato, M., Pierce, S., Keating, M.J., Freireich, E.J. & Estey, E. (2001) Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leukaemia & Lymphoma, 42, 67-73.
13. Glidewell, O. & Holland, J.F. (1975) Comparative prognosis of the acute leukemias. Bibliotheca Haematologica, 43, 527-530.
14. Huang, M.E., Ye, Y.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhoa, L., Gu, L.J. & Wang, Z.Y. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-572.
15. Jing, Y., Wang, L., Xia, L., Chen, G.Q., Chen, Z., Miller, W.H. & Waxman, S. (2001) Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood, 97, 264-269.
16. Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S.M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H.R., Cazzola, M., Melillo, L., Carella, A.M., Brandts, C.H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lubbert, M., Hanel, M., Schmitz, N., Link, H., Kropp, M.G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Dohner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Dohner, H., Ehninger, G., Schlenk, R.F. & Platzbecker, U., Gruppo Italiano Malattie Ematologiche dell'Adulto, German-Austrian Acute Myeloid Leukemia Study Group & Study Alliance Leukemia. (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New England Journal of Medicine, 369, 111-121.
17. Mathews, V., George, B., Lakshmi, K.M., Viswabandya, A., Bajel, A., Balasubramanian, P., Shaji, R.V., Srivastava, V.M., Srivastava, A. & Chandy, M. (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood, 107, 2627-2632.
18. Ravandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., Pierce, S., Blamble, D., Estrov, Z., Wierda, W., Ferrajoli, A., Verstovsek, S., Garcia-Manero, G., Cortes, J. & Kantarjian, H. (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of Clinical Oncology, 27, 504-510.
19. Sanz, M.A., Lo Coco, F., Martin, G., Avvisati, G., Rayon, C., Barbui, T., Diaz-Mediavilla, J., Fioritoni, G., Gonzalez, J.D., Liso, V., Esteve, J., Ferrara, F., Bolufer, P., Bernasconi, C., Gonzalez, M., Rodeghiero, F., Colomer, D., Petti, M.C., Ribera, J.M. & Mandelli, F. (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 96, 1247-1253.
20. Sanz, M.A., Grimwade, D., Tallman, M.S., Lowenberg, B., Fenaux, P., Estey, E.H., Naoe, T., Lengfelder, E., Buchner, T., Dohner, H., Burnett, A.K. & Lo-Coco, F. (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 113, 1875-1891.
21. Shen, Z.X., Chen, G.Q., Ni, J.H., Li, X.S., Xiong, S.M., Qiu, Q.Y., Zhu, J., Tang, W., Sun, G.L., Yang, K.Q., Chen, Y., Zhou, L., Fang, Z.W., Wang, Y.T., Ma, J., Zhang, P., Zhang, T.D., Chen, S.J., Chen, Z. & Wang, Z.Y. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, 3354-3360.
22. Shen, Z.X., Shi, Z.Z., Fang, J., Gu, B.W., Li, J.M., Zhu, Y.M., Shi, J.Y., Zheng, P.Z., Yan, H., Liu, Y.F., Chen, Y., Shen, Y., Wu, W., Tang, W., Waxman, S., De The, H., Wang, Z.Y., Chen, S.J. & Chen, Z. (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 101, 5328-5335.
23. Soignet, S.L., Frankel, S.R., Douer, D., Tallman, M.S., Kantarjian, H., Calleja, E., Stone, R.M., Kalaycio, M., Scheinberg, D.A., Steinherz, P., Sievers, E.L., Coutre, S., Dahlberg, S., Ellison, R. & Warrell, R.P. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology, 19, 3852-3860.
24. Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C.D., Rowe, J.M. & Wiernik, P.H. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine, 337, 1021-1028.
25. Thiebaut, A., Thomas, X., Belhabri, A., Anglaret, B. & Archimbaud, E. (2000) Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Annals of Hematology, 79, 501-506.
26. Vahdat, L., Maslak, P., Miller, W.H. Jr, Eardley, A., Heller, G., Scheinberg, D.A. & Warrell, R.P. Jr (1994) Early mortality and the retinoic acid syndrome in acute promye-locytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood, 84, 3843-3849.
27. Ventura, G.J., Hester, J.P., Smith, T.L. & Keating, M.J. (1988) Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. American Journal of Hematology, 27, 34-37.
28. Warrell, R.P. Jr, Frankel, S.R., Miller, W.H. Jr, Scheinberg, D.A., Itri, L.M., Hittelman, W.N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., Gabrilove, J., Gordon, M. & Dimitrovsky, E. (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New England Journal of Medicine, 324, 1385-1393.
29. Zuckerman, T., Ganzel, C., Tallman, M.S. & Rowe, J.M. (2012) How I treat hematologic emergencies in adults with acute leukemia. Blood, 120, 1993-2002.